A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs for pain and inflammation that fell into receivership last year.

Sun Pharma的一个子公司已达成协议，收购加拿大Antibe Therapeutics的资产。Antibe Therapeutics是一家治疗疼痛和炎症的药物开发公司，去年被破产。

The transaction would see Antibe taken over by Taro Pharmaceutical – which

这笔交易将被芋头制药接管

merged

合并

with Sun Pharma unit last year – but is subject to approval by the Ontario Superior Court of Justice, according to a

去年与Sun Pharma部门合作，但根据安大略省高级法院的批准

financial filing

财务备案

. The all-cash deal is expected to close by 7th March, but the value won't be disclosed until after completion due to Canada's receivership rules.

。这项全现金交易预计将于3月7日结束，但由于加拿大的破产管理规定，交易完成后才会披露其价值。

Antibe has been subject to a cease trade order under Ontario's securities legislation since July 24, after failing to file audited financial statements for the year ending 31st March 2024. The Toronto-based company struggled to secure backing from investors to keep the business operating as normal after the FDA placed a .

自7月24日以来，安提比省一直受到安大略省证券法规定的停业令的约束，因为安提比省未能提交截至2024年3月31日止年度的经审计财务报表。这家总部位于多伦多的公司在美国食品和药物管理局（FDA）宣布收购后，努力获得投资者的支持，以保持业务正常运营。

clinical hold

临床保留

on its lead drug otenaproxesul, blocking the start of a planned phase 2 trial.

在其主要药物奥替那普昔舒上，阻止了计划的第二阶段试验的开始。

Also complicating matters last year was a dispute with Shanghai biotech Nuance Pharma over a licensing agreement for otenaproxesul in the Greater China region, which resulted in an order for Antibe to refund a $20 million upfront fee and pay interest and costs of around $4 million.

去年，与上海生物技术Nuance Pharma就大中华地区奥替那普昔苏的许可协议发生纠纷，这也使事情变得复杂，导致Antibe被责令退还2000万美元的预付费，并支付约400万美元的利息和费用。

According to Antibe's most recent corporate update from 2024, otenaproxesul is a novel drug that pairs an anti-inflammatory hydrogen sulphide-releasing molecule with naproxen to create a better-tolerated alternative to current nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids for acute pain..

根据Antibe从2024年开始的最新公司更新，otenaproxesul是一种新型药物，它将抗炎性硫化氢释放分子与萘普生配对，以产生更好的耐受性，替代目前用于急性疼痛的非甾体类抗炎药（NSAIDs）和阿片类药物。。

The drug is designed to prevent the gastrointestinal toxicity encountered with NSAIDs and avoid issues like dependency that can occur with opioids. Antibe's plan was to develop the drug for acute pain indications – starting with abdominoplasty – after seeing a liver safety signal with chronic dosing in on osteoarthritis pain, whilst also exploring novel formulations to overcome the toxicity issue..

该药物旨在预防非甾体抗炎药引起的胃肠道毒性，并避免阿片类药物可能产生的依赖性等问题。Antibe的计划是在看到慢性给药治疗骨关节炎疼痛的肝脏安全信号后，开发用于急性疼痛适应症的药物-从腹部成形术开始，同时探索新的配方来克服毒性问题。。

Meanwhile, its pipeline also includes other drugs based on its hydrogen sulphide-releasing platform, including ATB-352 for an undisclosed specialised pain indication and early-stage research programmes for inflammatory bowel disease.

与此同时，其管道还包括基于其硫化氢释放平台的其他药物，包括用于未公开的专门疼痛适应症的ATB-352和炎症性肠病的早期研究计划。

It's not entirely clear what programmes will be included in the deal if Taro takes control of Antibe, as in the financial filing the company says its offer excludes some 'assets and liabilities' that will be transferred to a residual Antibe company.

目前尚不完全清楚，如果塔罗控股安提比，交易将包括哪些计划，因为该公司在财务文件中表示，其报价不包括将转移给剩余安提比公司的一些“资产和负债”。